Relationship Between the Gut Microbiome and Systemic Chemotherapy

Samantha M. Ervin, Siddharth Venkat Ramanan, Aadra P. Bhatt

Research output: Contribution to journalReview articlepeer-review

25 Citations (SciVal)


The intestinal microbiome encodes vast metabolic potential, and multidisciplinary approaches are enabling a mechanistic understanding of how bacterial enzymes impact the metabolism of diverse pharmaceutical compounds, including chemotherapeutics. Microbiota alter the activity of many drugs and chemotherapeutics via direct and indirect mechanisms; some of these alterations result in changes to the drug’s bioactivity and bioavailability, causing toxic gastrointestinal side effects. Gastrointestinal toxicity is one of the leading complications of systemic chemotherapy, with symptoms including nausea, vomiting, diarrhea, and constipation. Patients undergo dose reductions or drug holidays to manage these adverse events, which can significantly harm prognosis, and can result in mortality. Selective and precise targeting of the gut microbiota may alleviate these toxicities. Understanding the composition and function of the microbiota may serve as a biomarker for prognosis, and predict treatment efficacy and potential adverse effects, thereby facilitating personalized medicine strategies for cancer patients.

Original languageEnglish
Pages (from-to)874-884
JournalDigestive Diseases and Sciences
Issue number3
Publication statusPublished - 01-03-2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Relationship Between the Gut Microbiome and Systemic Chemotherapy'. Together they form a unique fingerprint.

Cite this